NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free CDNA Stock Alerts $15.50 +0.72 (+4.87%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$14.82▼$15.5850-Day Range$7.56▼$15.5052-Week Range$4.80▼$16.15Volume883,691 shsAverage Volume979,504 shsMarket Capitalization$807.24 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CareDx alerts: Email Address CareDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside6.5% Upside$16.50 Price TargetShort InterestBearish10.57% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.33Based on 27 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.59) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector465th out of 919 stocksMedical Laboratories Industry12th out of 19 stocks 2.3 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CareDx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.57% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in CareDx has recently increased by 9.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 3.0 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for CareDx this week, compared to 3 articles on an average week.Search Interest13 people have searched for CDNA on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.MarketBeat Follows5 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders.Read more about CareDx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.59) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CareDx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesMay 18 at 1:43 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Shares Gap Up After Analyst UpgradeMay 17 at 6:34 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Rating Reiterated by HC WainwrightMay 16 at 5:40 PM | finance.yahoo.comLandmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer BiopsiesMay 16 at 4:05 PM | businesswire.comLandmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer BiopsiesMay 15 at 4:37 PM | markets.businessinsider.comMaintaining Hold on CareDx Amid Growth, Valuation, and Uncertainty ConcernsMay 15 at 4:37 PM | markets.businessinsider.comBalanced Outlook for CareDx: Strong Performance Amid Rising CompetitionMay 15 at 10:21 AM | insidermonkey.comHere’s Why Baron Discovery Fund Reinitiated the Position in CareDx (CDNA)May 15 at 4:36 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Rating Lowered to Market Perform at Raymond JamesMay 15 at 4:36 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Price Target Raised to $14.00May 15 at 4:01 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Price Target Raised to $18.00 at StephensMay 15 at 12:19 AM | markets.businessinsider.comBuy Rating Justified: CareDx’s Strong Financial Performance and Market PotentialMay 14, 2024 | msn.comRaymond James Downgrades CareDx (CDNA)May 13, 2024 | msn.comCareDx cut to market perform by Raymond James over valuationMay 13, 2024 | markets.businessinsider.comNavigating 5 Analyst Ratings For CareDxMay 13, 2024 | americanbankingnews.comCareDx's (CDNA) "Buy" Rating Reiterated at Craig HallumMay 12, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Stock Rating Upgraded by StockNews.comMay 12, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Sets New 1-Year High at $15.30May 11, 2024 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their CareDx, Inc (NASDAQ:CDNA) Price Target To US$13.80May 10, 2024 | finance.yahoo.comCareDx Reports Mixed Q1 2024 Results; Raises Annual Revenue GuidanceMay 10, 2024 | finance.yahoo.comCareDx, Inc (NASDAQ:CDNA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | seekingalpha.comCareDx, Inc 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | businesswire.comCareDx Reports First Quarter 2024 ResultsMay 3, 2024 | businesswire.comCareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | msn.comCraig-Hallum Upgrades CareDx (CDNA)April 29, 2024 | finance.yahoo.comCareDx to Report First Quarter 2024 Financial ResultsSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees635Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$22.00 Low Stock Price Target$12.00 Potential Upside/Downside+6.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,280,000.00 Net Margins-66.59% Pretax Margin-66.61% Return on Equity-55.08% Return on Assets-37.48% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.03 Sales & Book Value Annual Sales$280.32 million Price / Sales2.88 Cash FlowN/A Price / Cash FlowN/A Book Value$4.92 per share Price / Book3.15Miscellaneous Outstanding Shares52,080,000Free Float49,896,000Market Cap$807.24 million OptionableOptionable Beta1.51 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 47)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 57)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 50)President of Patient & Testing Services Comp: $547.43kMr. John Walter Hanna Jr. (Age 44)President, CEO & Director Ms. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerJeffrey A. NovackGeneral CounselMs. Stacey FollonSenior VP & Head of Human ResourcesMr. Kashif RathoreChief of Patient & Digital SolutionsMore ExecutivesKey CompetitorsFulgent GeneticsNASDAQ:FLGTCastle BiosciencesNASDAQ:CSTLViridian TherapeuticsNASDAQ:VRDNCelcuityNASDAQ:CELCSera PrognosticsNASDAQ:SERAView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Bought 92,363 shares on 5/16/2024Ownership: 2.210%Caxton Associates LPBought 47,469 shares on 5/16/2024Ownership: 0.185%California State Teachers Retirement SystemSold 3,333 shares on 5/16/2024Ownership: 0.010%Price T Rowe Associates Inc. MDBought 2,344 shares on 5/15/2024Ownership: 0.056%Public Employees Retirement Association of ColoradoSold 847 shares on 5/15/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions Should I buy or sell CareDx stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDNA shares. View CDNA analyst ratings or view top-rated stocks. What is CareDx's stock price target for 2024? 5 brokerages have issued 1 year price targets for CareDx's shares. Their CDNA share price targets range from $12.00 to $22.00. On average, they predict the company's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price. View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts. How have CDNA shares performed in 2024? CareDx's stock was trading at $12.00 at the beginning of 2024. Since then, CDNA stock has increased by 29.2% and is now trading at $15.50. View the best growth stocks for 2024 here. When is CareDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CDNA earnings forecast. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($2.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $1.97. The business had revenue of $65.57 million for the quarter, compared to analysts' expectations of $63.66 million. CareDx had a negative trailing twelve-month return on equity of 55.08% and a negative net margin of 66.59%. The business's quarterly revenue was down 20.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.34) earnings per share. What ETFs hold CareDx's stock? ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include Jacob Forward ETF (JFWD) and ARK Genomic Revolution ETF (ARKG).Global X Genomics & Biotechnology ETF (GNOM). What guidance has CareDx issued on next quarter's earnings? CareDx updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $274.0 million-$282.0 million, compared to the consensus revenue estimate of $267.0 million. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA). Who are CareDx's major shareholders? CareDx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.30%), Bellevue Group AG (7.55%), Sumitomo Mitsui Trust Holdings Inc. (5.31%), Nikko Asset Management Americas Inc. (5.31%), Gagnon Securities LLC (4.31%) and Bamco Inc. NY (2.36%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDNA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.